The patient group's push for FTA scrutiny isn't just public health advocacy; it's a direct...

The patient group's push for FTA scrutiny isn't just public health advocacy; it's a direct challenge to India's generic pharma model. TRIPS-plus provisions like patent extensions threaten our core strength: affordable medicine access. Longer monopolies mean delayed generic entry, impacting market share and export potential. This negotiation will redefine our IP landscape and global competitiveness. Strategic planning is crucial now.

https://pharma.economictimes.indiatimes.com/news/pharma-industry/patient-group-seeks-public-scrutiny-of-india-eu-fta/127748965